Search research articles
Contact Us
Filters
Showing results (141-150 of 397) with videos related to
Page
of 40
Sort By:
Journal for Immunotherapy of Cancer
|
August 27, 2020
Preclinical investigations and a first-in-human phase I trial of M4112, the first dual inhibitor of indoleamine 2,3-dioxygenase 1 and tryptophan 2,3-dioxygenase 2, in patients with advanced solid tumors
Aung Naing, Joseph P Eder, Sarina A Piha-Paul, et al.
Plos One
|
June 8, 2012
KRASness and PIK3CAness in patients with advanced colorectal cancer: outcome after treatment with early-phase trials with targeted pathway inhibitors
Ignacio Garrido-Laguna, David S Hong, Filip Janku, et al.
Molecular Cancer Therapeutics
|
May 17, 2011
Phase I trial of hepatic arterial infusion of nanoparticle albumin-bound paclitaxel: toxicity, pharmacokinetics, and activity
Siqing Fu, Aung Naing, Stacy L Moulder, et al.
Gynecologic Oncology
|
June 15, 2020
Phase II study of pembrolizumab efficacy and safety in women with recurrent small cell neuroendocrine carcinoma of the lower genital tract
Michael Frumovitz, Shannon N Westin, Gloria Salvo, et al.
Investigational New Drugs
|
December 6, 2013
Exploratory study of carboplatin plus the copper-lowering agent trientine in patients with advanced malignancies
Siqing Fu, Ming-Mo Hou, Jennifer Wheler, et al.
NPJ Precision Oncology
|
June 12, 2026
Genomic co-alterations and immune-related adverse events shape outcomes of thymic malignancies treated with immune checkpoint inhibitors
Harold Nathan Tan, Hung Le, Khaoula Ben Haj Frej, et al.
Oncotarget
|
June 15, 2013
Thymoma patients treated in a phase I clinic at MD Anderson Cancer Center: responses to mTOR inhibitors and molecular analyses
Jennifer Wheler, David Hong, Stephen G Swisher, et al.
Journal for Immunotherapy of Cancer
|
January 11, 2021
Efficacy of pembrolizumab in patients with pituitary carcinoma: report of four cases from a phase II study
Nazanin Majd, Steven G Waguespack, Filip Janku, et al.
Journal of Cancer
|
February 18, 2011
Phase I Dose Escalation Study of Sodium Stibogluconate (SSG), a Protein Tyrosine Phosphatase Inhibitor, Combined with Interferon Alpha for Patients with Solid Tumors
Aung Naing, James M Reuben, Luis H Camacho, et al.
Investigational New Drugs
|
August 3, 2013
Methylation and histone deacetylase inhibition in combination with platinum treatment in patients with advanced malignancies
Gerald S Falchook, Siqing Fu, Aung Naing, et al.
Page
of 40
Search research articles
Search
Showing results (141-150 of 397) with videos related to
Sort By:
Page
of 40
Journal for Immunotherapy of Cancer
|
August 27, 2020
Preclinical investigations and a first-in-human phase I trial of M4112, the first dual inhibitor of indoleamine 2,3-dioxygenase 1 and tryptophan 2,3-dioxygenase 2, in patients with advanced solid tumors
Aung Naing, Joseph P Eder, Sarina A Piha-Paul, et al.
Plos One
|
June 8, 2012
KRASness and PIK3CAness in patients with advanced colorectal cancer: outcome after treatment with early-phase trials with targeted pathway inhibitors
Ignacio Garrido-Laguna, David S Hong, Filip Janku, et al.
Molecular Cancer Therapeutics
|
May 17, 2011
Phase I trial of hepatic arterial infusion of nanoparticle albumin-bound paclitaxel: toxicity, pharmacokinetics, and activity
Siqing Fu, Aung Naing, Stacy L Moulder, et al.
Gynecologic Oncology
|
June 15, 2020
Phase II study of pembrolizumab efficacy and safety in women with recurrent small cell neuroendocrine carcinoma of the lower genital tract
Michael Frumovitz, Shannon N Westin, Gloria Salvo, et al.
Investigational New Drugs
|
December 6, 2013
Exploratory study of carboplatin plus the copper-lowering agent trientine in patients with advanced malignancies
Siqing Fu, Ming-Mo Hou, Jennifer Wheler, et al.
NPJ Precision Oncology
|
June 12, 2026
Genomic co-alterations and immune-related adverse events shape outcomes of thymic malignancies treated with immune checkpoint inhibitors
Harold Nathan Tan, Hung Le, Khaoula Ben Haj Frej, et al.
Oncotarget
|
June 15, 2013
Thymoma patients treated in a phase I clinic at MD Anderson Cancer Center: responses to mTOR inhibitors and molecular analyses
Jennifer Wheler, David Hong, Stephen G Swisher, et al.
Journal for Immunotherapy of Cancer
|
January 11, 2021
Efficacy of pembrolizumab in patients with pituitary carcinoma: report of four cases from a phase II study
Nazanin Majd, Steven G Waguespack, Filip Janku, et al.
Journal of Cancer
|
February 18, 2011
Phase I Dose Escalation Study of Sodium Stibogluconate (SSG), a Protein Tyrosine Phosphatase Inhibitor, Combined with Interferon Alpha for Patients with Solid Tumors
Aung Naing, James M Reuben, Luis H Camacho, et al.
Investigational New Drugs
|
August 3, 2013
Methylation and histone deacetylase inhibition in combination with platinum treatment in patients with advanced malignancies
Gerald S Falchook, Siqing Fu, Aung Naing, et al.
Page
of 40